I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 1.085 USD 4.33%
Market Cap: 87.8m USD
Have any thoughts about
I-Mab?
Write Note

Intrinsic Value

IMAB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IMAB stock under the Base Case scenario is 0.775 USD. Compared to the current market price of 1.085 USD, I-Mab is Overvalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IMAB Intrinsic Value
0.775 USD
Overvaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
I-Mab

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IMAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IMAB?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about I-Mab

Provide an overview of the primary business activities
of I-Mab.

What unique competitive advantages
does I-Mab hold over its rivals?

What risks and challenges
does I-Mab face in the near future?

Summarize the latest earnings call
of I-Mab.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for I-Mab.

Provide P/S
for I-Mab.

Provide P/E
for I-Mab.

Provide P/OCF
for I-Mab.

Provide P/FCFE
for I-Mab.

Provide P/B
for I-Mab.

Provide EV/S
for I-Mab.

Provide EV/GP
for I-Mab.

Provide EV/EBITDA
for I-Mab.

Provide EV/EBIT
for I-Mab.

Provide EV/OCF
for I-Mab.

Provide EV/FCFF
for I-Mab.

Provide EV/IC
for I-Mab.

Show me price targets
for I-Mab made by professional analysts.

What are the Revenue projections
for I-Mab?

How accurate were the past Revenue estimates
for I-Mab?

What are the Net Income projections
for I-Mab?

How accurate were the past Net Income estimates
for I-Mab?

What are the EPS projections
for I-Mab?

How accurate were the past EPS estimates
for I-Mab?

What are the EBIT projections
for I-Mab?

How accurate were the past EBIT estimates
for I-Mab?

Compare the revenue forecasts
for I-Mab with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of I-Mab and its key competitors using the latest financial data.

Compare historical revenue growth rates
of I-Mab against its competitors.

Analyze the profit margins
(gross, operating, and net) of I-Mab compared to its peers.

Compare the P/E ratios
of I-Mab against its peers.

Discuss the investment returns and shareholder value creation
comparing I-Mab with its peers.

Analyze the financial leverage
of I-Mab compared to its main competitors.

Show all profitability ratios
for I-Mab.

Provide ROE
for I-Mab.

Provide ROA
for I-Mab.

Provide ROIC
for I-Mab.

Provide ROCE
for I-Mab.

Provide Gross Margin
for I-Mab.

Provide Operating Margin
for I-Mab.

Provide Net Margin
for I-Mab.

Provide FCF Margin
for I-Mab.

Show all solvency ratios
for I-Mab.

Provide D/E Ratio
for I-Mab.

Provide D/A Ratio
for I-Mab.

Provide Interest Coverage Ratio
for I-Mab.

Provide Altman Z-Score Ratio
for I-Mab.

Provide Quick Ratio
for I-Mab.

Provide Current Ratio
for I-Mab.

Provide Cash Ratio
for I-Mab.

What is the historical Revenue growth
over the last 5 years for I-Mab?

What is the historical Net Income growth
over the last 5 years for I-Mab?

What is the current Free Cash Flow
of I-Mab?

Discuss the annual earnings per share (EPS)
trend over the past five years for I-Mab.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
I-Mab

Current Assets 2.3B
Cash & Short-Term Investments 2.3B
Other Current Assets 52m
Non-Current Assets 276.3m
Long-Term Investments 12.1m
PP&E 82.9m
Intangibles 118.1m
Other Non-Current Assets 63.2m
Current Liabilities 411.8m
Accounts Payable 357.8m
Accrued Liabilities 21.9m
Short-Term Debt 30m
Other Current Liabilities 2.2m
Non-Current Liabilities 483m
Other Non-Current Liabilities 483m
Efficiency

Earnings Waterfall
I-Mab

Revenue
27.6m CNY
Cost of Revenue
0 CNY
Gross Profit
27.6m CNY
Operating Expenses
-1.3B CNY
Operating Income
-1.2B CNY
Other Expenses
-229.7m CNY
Net Income
-1.5B CNY

Free Cash Flow Analysis
I-Mab

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IMAB Profitability Score
Profitability Due Diligence

I-Mab's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Gross Profit
Exceptional ROIC
ROIC is Increasing
36/100
Profitability
Score

I-Mab's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

IMAB Solvency Score
Solvency Due Diligence

I-Mab's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
53/100
Solvency
Score

I-Mab's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMAB Price Targets Summary
I-Mab

Wall Street analysts forecast IMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMAB is 6.885 USD with a low forecast of 5.05 USD and a high forecast of 8.4 USD.

Lowest
Price Target
5.05 USD
365% Upside
Average
Price Target
6.885 USD
535% Upside
Highest
Price Target
8.4 USD
674% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IMAB?

Click here to dive deeper.

Dividends

I-Mab
does not pay dividends
Shareholder Yield

Current shareholder yield for IMAB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

I-Mab Logo
I-Mab

Country

China

Industry

Biotechnology

Market Cap

87.4m USD

Dividend Yield

0%

Description

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

Contact

SHANGHAI
Shanghai
55Th-56Th Floor, New Bund Center, 555 West Haiyang Road, Pudong District
+862160578000.0
www.i-mabbiopharma.com

IPO

2020-01-17

Employees

228

Officers

Director & Interim CEO
Dr. Xi-Yong Fu M.B.A., Ph.D.
Chief Financial Officer
Mr. Skelton Joseph
Vice President of Investor Relations
Mr. Tianyi Zhang
Senior VP and Head of U.S. & EU Business Development
Dr. Fernando J. Salle´s Ph.D.
Interim Chief Medical Officer
Dr. Louie Naumovski M.D., Ph.D.
Chief Medical Officer
Dr. Phillip Dennis M.D., Ph.D.
Show More
Senior Director of Investor Relations
Mr. Tyler Ehler
Show Less

See Also

Discover More
What is the Intrinsic Value of one IMAB stock?

The intrinsic value of one IMAB stock under the Base Case scenario is 0.775 USD.

Is IMAB stock undervalued or overvalued?

Compared to the current market price of 1.085 USD, I-Mab is Overvalued by 29%.

Back to Top